Titre
Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward.
Type
synthèse (review)
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Jenei, K.
Auteure/Auteur
Aziz, Z.
Auteure/Auteur
Booth, C.
Auteure/Auteur
Cappello, B.
Auteure/Auteur
Ceppi, F.
Auteure/Auteur
de Vries, EGE
Auteure/Auteur
Fojo, A.
Auteure/Auteur
Gyawali, B.
Auteure/Auteur
Ilbawi, A.
Auteure/Auteur
Lombe, D.
Auteure/Auteur
Sengar, M.
Auteure/Auteur
Sullivan, R.
Auteure/Auteur
Trapani, D.
Auteure/Auteur
Huttner, B.D.
Auteure/Auteur
Moja, L.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
2214-109X
Statut éditorial
Publié
Date de publication
2022-12
Volume
10
Numéro
12
Première page
e1860
Dernière page/numéro d’article
e1866
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Résumé
The selection of cancer medicines for national procurement requires deliberate evaluation of population benefit, budget impact, sustainability, and health system capacity. However, this process is complicated by numerous challenges, including the large volume and rapid pace of newly developed therapies offering marginal gains at prohibitively high prices. The WHO Model List of Essential Medicines (EML) and Model List of Essential Medicines for Children (EMLc) have undergone a series of evidence-based updates to ensure recommended cancer medicines offer meaningful clinical benefit. This Health Policy paper describes how cancer medicines are listed on the EML and EMLc, including two updated WHO processes: (1) the formation of the Cancer Medicines Working Group, and (2) additional selection principles for recommending cancer medicines, including a minimum overall survival benefit of 4-6 months with improvement to quality of life compared with standard treatment. These updates, along with proposals to include formal price considerations, additional selection criteria, and multisectoral collaboration (eg, voluntary licensing) promote procurement of high-value essential cancer medicines on national formularies in the context of supporting sustainable health systems to achieve universal health coverage.
PID Serval
serval:BIB_A5D2D166DA1B
PMID
Open Access
Oui
Date de création
2022-10-11T11:29:17.643Z
Date de création dans IRIS
2025-05-21T04:16:25Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
36183737.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by-nc-nd/4.0
Taille
1.24 MB
Format
Adobe PDF
PID Serval
serval:BIB_A5D2D166DA1B.P001
URN
urn:nbn:ch:serval-BIB_A5D2D166DA1B1
Somme de contrôle
(MD5):1581319b95fde61f86c6f914b504b6f1